Impact of Serum HE4 Detection in Endometrial Carcinoma
Author Information
Author(s): Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi R A, Romani C, Todeschini P, Odicino F E, Facchetti F, Pecorelli S, Ravaggi A
Primary Institution: University of Brescia
Hypothesis
To investigate HE4 gene, protein expression and serum HE4 levels in endometrial carcinoma and correlate it with patient characteristics and prognosis.
Conclusion
High serum HE4 levels correlate with an aggressive endometrial carcinoma phenotype and may serve as an independent prognostic factor.
Supporting Evidence
- High sHE4 levels were significantly associated with worse clinical characteristics in endometrial carcinoma patients.
- High sHE4 levels correlated with decreased overall survival, progression-free survival, and disease-free survival.
- HE4 showed higher sensitivity compared to CA125 for detecting endometrial carcinoma.
Takeaway
This study found that a protein called HE4 in the blood can help doctors tell how serious endometrial cancer is, which can help in deciding treatment.
Methodology
The study used quantitative real-time PCR, immunohistochemistry, and serum analysis to evaluate HE4 levels in endometrial carcinoma and normal tissues.
Potential Biases
Potential bias in patient selection and the retrospective nature of the study.
Limitations
The study focused on a specific cohort and may not generalize to all endometrial carcinoma patients.
Participant Demographics
Patients included 138 with endometrial carcinoma and 76 healthy controls, with a median follow-up of 33.1 months.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 1.78–3.88
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website